Ensorcell (ensorcell.bio), a US-based company focused on reimaging life science tools and solutions for the biopharmaceutical industry, announced on Tuesday the appointments of Geoff Hodge and Amy Teachout to its senior leadership team.
Hodge is named head of Technology, responsible for accelerating high impact innovation across the company's technology and product development initiatives. He brings decades of experience spanning biopharmaceutical research, development, manufacturing, and technology leadership from his experience as co-founder of Xcellerex, CEO of SOTIO Biotech, and CTO of Unum Therapeutics. His focus at Ensorcell will be on translating novel concepts into scalable solutions that help partners advance programs efficiently from development through manufacturing.
Teachout has been appointed head of Customer Excellence, with responsibility for ensuring seamless, high-quality customer care across the full client engagement lifecycle. She brings extensive experience in program leadership, commercialisation support, logistics, and customer care.
Jeff Goldman, Ensorcell general manager, said: "Geoff and Amy bring deep industry expertise and complementary leadership strengths. Geoff's focus on accelerating high-impact breakthroughs and Amy's leadership in customer excellence directly support Ensorcell's mission to deliver meaningful, reliable outcomes for our biopharma partners."
HUTCHMED secures priority review for sovleplenib NDA in China
Chiesi Group to acquire KalVista Pharmaceuticals for USD1.9bn in rare disease expansion strategy
Circio partners with USC to advance non-viral RNA delivery technologies
Cirius Therapeutics introduces gestational diabetes initiative
Vanda Pharmaceuticals reports publication of imsidolimab phase III findings in NEJM Evidence
GSK hepatitis B therapy bepirovirsen gains FDA priority review and breakthrough designation
Boehringer Ingelheim's survodutide phase 3 data show significant weight loss in obesity trial
Novartis secures European approval for remibrutinib in chronic spontaneous urticaria
GSK secures US and EU fast-track designations for efimosfermin in MASH
Shield Therapeutics announces Phase II trial initiation of ACCRUFeR in Japan for PAH
Veradermics reports positive Phase 2/3 results for oral VDPHL01 in pattern hair loss treatment
Thermo Fisher scientific agrees to sell microbiology business to Astorg